可吸收丙酸氟替卡松缓释鼻窦敷料在ESS术后管理中的安全性与疗效:一项随机临床试验
这项首次人体、随机、部分双盲、单三级转诊中心对照试验纳入30例伴鼻息肉的慢性鼻窦炎(CRS)患者,每侧鼻腔随机接受SinuBand FP、SinuBand(不含FP)或标准鼻腔填塞(Merocel®)之一。SinuBand FP显示局部和眼部安全性良好,24小时尿皮质醇无显著变化;息肉评分显著优于Merocel(p=0.03),但与不含激素的SinuBand相比无显著差异(p=0.97)。
要点
- SinuBand FP在ESS术后显示局部与眼部安全性良好,24小时尿皮质醇无显著变化。
- 息肉评分SinuBand FP显著优于Merocel(p=0.03),与不含激素SinuBand无显著差异(p=0.97)。
- 炎症方面SinuBand FP显示改善趋势,粘连在各治疗间相当,疼痛在SinuBand组名义上更低。
核心结论
- SinuBand FP耐受性良好并显示疗效证据,需更大规模研究进一步评估和确认其获益。
研究设计与样本
- 首次人体、随机、部分双盲、单三级转诊中心对照试验,纳入30例伴鼻息肉且适合双侧前后筛窦切除术的CRS患者。
- 每例患者接受三种治疗中的两种(每侧鼻窦一种,患者内对照):SinuBand FP、SinuBand(不含FP)或标准鼻腔填塞(Merocel®)。
- 30例纳入安全性分析,27例完成试验。
主要发现
- SinuBand FP显示局部安全性、眼部安全性,24小时尿皮质醇无显著变化。
- SinuBand FP在炎症方面显示改善趋势。
- 息肉评分:SinuBand FP显著优于Merocel(p=0.03),与不含激素的SinuBand相比无显著差异(p=0.97)。
- 粘连在各治疗间相当。
- 患者报告的疼痛在SinuBand组名义上更低。
关键数值与推荐
- 主要结局指标为局部安全性、眼部安全性(眼内压[IOP]、晶状体混浊度)和24小时尿皮质醇。
- 次要指标包括筛窦炎症、息肉评分、粘连形成和Lund-Kennedy评分,由术后视频内镜独立审阅评估。
- 患者报告结局包括术后疼痛、鼻塞和鼻漏。
临床怎么用
- SinuBand FP可用于伴鼻息肉的CRS患者ESS术后管理,显示局部与眼部安全性良好且24小时尿皮质醇无显著变化。
- SinuBand FP在息肉评分上显著优于Merocel,但与不含激素的SinuBand相比无显著差异。
- 炎症改善仅为趋势,粘连各治疗相当,疼痛在SinuBand组名义上更低。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative wound healing after endoscopic sinus surgery (ESS) in patients with chronic rhinosinusitis (CRS) is an important factor in procedural success. Local steroids and separation of opposing mucosa are commonly implemented to optimize healing. A bioabsorbable, fluticasone propionate (FP)-eluting implant, SinuBand FP, was assessed for its safety and efficacy when used in patients with CRS and nasal polyps, who were indicated for ESS including bilateral anterior and posterior ethmoidectomy. METHODS: A first-in-human, randomized, partially double-blind, single-tertiary-referral-center, controlled trial enrolling 30 patients receiving 2 of 3 treatments (1 per sinus, intrapatient control): SinuBand FP, SinuBand (without FP), or standard nasal pack (Merocel®). Primary outcome measures were local safety, ocular safety (intraocular pressure [IOP], lens opacity), and 24-hour urine cortisol. Secondary measures (evaluated by independent review of postoperative video endoscopies) were ethmoid inflammation, polyp score, adhesion formation, and Lund-Kennedy score. Patient-reported outcomes of postoperative pain, nasal congestion, and nasal discharge were collected. RESULTS: Of 30 enrolled patients (used for safety analysis), 27 patients completed the trial. SinuBand FP showed local safety, ocular safety, and no significant change in 24-hour urine cortisol. SinuBand FP showed a trend to do better concerning inflammation. Concerning polyp score SinuBand FP did significantly better compared to Merocel (p = 0.03). No significance compared to SinuBand without corticosteroids (p = 0.97). Adhesions were comparable across treatments. Patient reported pain was nominally lower in the SinuBand group. CONCLUSION: SinuBand FP was well tolerated and showed evidence of efficacy. A larger study is needed to further evaluate and confirm the benefits of SinuBand FP.
引用
- Adriaensen GFJPM, Lim KH, Fokkens WJ, et al. Safety and efficacy of a bioabsorbable fluticasone propionate-eluting sinus dressing in postoperative management of endoscopic sinus surgery: a randomized clinical trial. Int Forum Allergy Rhinol. 2017. PMID: 28558147. doi:10.1002/alr.21963
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。